The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Onconetix, Inc. (NASDAQ:ONCO), a pharmaceutical company with a market capitalization of $4.48 million, has reached a settlement agreement with IQVIA, Inc., a provider of advanced analytics ...

Onconetix (NASDAQ:ONCO) just reported results for the first quarter of 2024. Onconetix reported earnings per share of -50 cents. The company reported revenue of $700,433. InvestorPlace Earnings is ...

06:17 EST Onconetix (ONCO) files to sell 50M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now ...

Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6 ...

Short interest in Onconetix Inc (NASDAQ:ONCO) decreased during the last reporting period, falling from 1.33M to 193.86K. This put 1.78% of the company's publicly available shares short.

Onconetix, Inc., a pharmaceutical preparations company with a market capitalization of $4.48 million, has entered into a material definitive agreement and created a direct financial obligation, ...

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...